Table 4 Meta-analysis of treatment received between survivor and non-survivor kidney transplantation patients.
Variables | Survivors | Non-survivors | Number of patients reported | Number of studies reporting | Pooled odds ratio (95% CI) | p-value from random effects model | I2 index (%) | Q-test p-value | Egger’s test p-value |
|---|---|---|---|---|---|---|---|---|---|
Ventilator support or intubation (%) | 68 (5.3) | 224 (64.0) | 1,645 | 6 | 56.45 (9.67, 329.62) | < 0.001 | 93.1 | < 0.001 | 0.007 |
Withhold CNIs (%) | 32 (6.9) | 46 (39.3) | 582 | 4 | 10.07 (0.76, 132.62) | 0.08 | 93.1 | < 0.001 | < 0.001 |
Withhold antimetabolites (%) | 379 (75.2) | 110 (84.6) | 634 | 5 | 1.66 (0.92, 2.99) | 0.09 | 0 | 0.39 | 0.46 |
Hydroxychloroquine (%) | 716 (55.3) | 226 (64.6) | 1,645 | 6 | 1.55 (1.20, 2.00) | < 0.001 | 0 | 0.38 | 0.29 |
Steroid (%) | 550 (42.5) | 240 (68.6) | 1,645 | 6 | 4.40 (1.70, 11.38) | 0.002 | 81.6 | 0.002 | 0.014 |
Antibiotics (%) | 553 (44.0) | 169 (50.1) | 1,593 | 5 | 1.91 (1.06, 3.46) | 0.031 | 46.3 | 0.10 | 0.013 |
Antivirals (%) | 273 (21.1) | 107 (30.6) | 1,645 | 6 | 1.99 (1.36, 2.93) | < 0.001 | 15.8 | 0.17 | 0.15 |
Tocilizumab (%) | 120 (9.3) | 90 (25.7) | 1,645 | 6 | 5.40 (1.54, 18.88) | 0.008 | 88.1 | < 0.001 | 0.88 |
Convalescent plasma (%) | 8 (2.6) | 15 (21.4) | 381 | 3 | 8.76 (1.85, 41.5) | 0.006 | 56.2 | 0.10 | 0.86 |
